<DOC>
	<DOCNO>NCT00557518</DOCNO>
	<brief_summary>Based upon preclinical evidence model diabetic nephropathy condition approximate type I II diabetes , treatment alagebrium appear favorable advantageous effect biochemical , structural , pathological functional hallmark diabetic nephropathy . The renoprotective effect alagebrium preclinical model favor evaluation drug patient type I diabetes .</brief_summary>
	<brief_title>Study Alagebrium Patients With Insulin-Dependent Type 1 Diabetes Microalbuminuria</brief_title>
	<detailed_description>This study double-blind , randomize , placebo-controlled , parallel design trial enrol 80 patient ( 2x40 ) Type 1 diabetes microalbuminuria . Patients randomize either 200 mg Alagebrium twice daily placebo period 24 week 8 week run-in period . There 8 week run-out period . All patient receive ramipril entire study period . Efficacy measurement perform baseline , 12 week end study . Measurements albumin : creatinine ratio ( mg/g ) , plasma renin level , collagen marker , AGE relate marker 24 hour blood pressure measurement also determine . A total 9 visit perform entire study .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>Insulindependent type 1 diabetes Age 1865 year Diagnosis establish microalbuminuria Blood pressure &lt; 140 mm Hg , diastolic blood pressure &lt; 90 mm Hg HbA1c &lt; 10 % Body mass index &gt; 40 kg/m2 Cardiovascular event within 6 month prior screen History acute myocardial infarction within 12 month prior screen Serum creatinine &gt; 1.5 mg/dL Receiving chronic nonsteroidal antiinflammatory therapy Receiving antihypertensive therapy except angiotensin convert enzyme inhibitor angiotensin receptor blocker Any significant systemic illness , medical condition abnormal laboratory value</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>